An Immune‐Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.11.2026. Verfasst von Sijia Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Cultivation Project of the Joint Fund of the Heilongjiang Provincial Natural Science Foundation, the Heilongjiang Provincial General Postdoctoral Funding Program, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Breast cancer progression reflects coupled immune and metabolic reprogramming, but biomarkers that capture this interplay and provide additional prognostic information beyond routine clinicopathological assessment remain limited. We developed an 11‐gene immune–metabolic risk Score in TCGA‐BRCA ( n = 1099) by integrating C7 immune signatures and KEGG metabolic pathways through Cox and LASSO‐Cox modeling. The fixed model was applied without retraining to three public cohorts and an independent institutional cohort of 146 patients from Harbin Medical University Cancer Hospital. The score consistently stratified overall survival across independent cohorts and provided additional prognostic information beyond conventional clinicopathological variables. Integrative analyses showed that high‐risk tumors were characterized by enhanced cell‐cycle and metabolic activation, reduced lymphocyte‐associated immune features, and monocytic‐lineage enrichment. At single‐cell resolution, high‐score cancer‐associated fibroblasts exhibited enhanced extracellular‐matrix remodeling, inflammatory iCAF activity, and TGF‐β‐associated immunosuppressive programs. In an exploratory pembrolizumab‐containing cohort, lower pretreatment scores were associated with pathological complete response and immune‐active transcriptional programs; however, these findings do not establish the score as a predictive biomarker for immunotherapy benefit. The 11‐gene immune–metabolic risk Score provides complementary prognostic stratification beyond conventional clinical variables and characterizes a stromal‐remodeled immune–metabolic state associated with adverse breast cancer outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
- Scientific Research Center, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China.
ORCID-Profile: He Ren
Förderung
- the Cultivation Project of the Joint Fund of the Heilongjiang Provincial Natural Science Foundation
- the Heilongjiang Provincial General Postdoctoral Funding Program
- China Postdoctoral Science Foundation
Zitieren
APA
Dong, S., Xu, W., Liu, S., Zhang, K., Deng, K., Li, Z., & Ren, H. (2026). An Immune‐Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72465
Vancouver
Dong S, Xu W, Liu S, Zhang K, Deng K, Li Z, et al. An Immune‐Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72465
BibTeX
@article{Dong2026,
author = {Dong, Sijia and Xu, Wenxiao and Liu, Shan and Zhang, Kun and Deng, Kaihong and Li, Zhigao and Ren, He},
title = {An Immune‐Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72465}
}
EUVIMED